H growth factors acting on primitive hematopoietic cells lodged predominantly within the bone marrow (BM) microenvironment. Stem cell factor (also known as kit ligand, mast-cell growth factor, or steel factor) acts in concert with more lineage-specific growth factors to stimulate the growth of hematopoietic stem cells and progenitor cells.'-s Although human SCF displays modest colony growth-promoting effect when used alone under serum-free conditions, it markedly potentiates the effects of erythropoietin (Epo), interleukin-3 (IL-3), granulocyte-macrophage colony-stimulating factor (GM-CSF), G-CSF, and IL-11 in vitro."' Extensive studies with enriched populations of marrow cells indicate that the cellular targets for stem-cell factor (SCF) include hematopoietic stem cells and progenitor cells.2*336-8 These characteristics make SCF a potentially attractive agent in the clinical setting of BM transplantation or other high-dose chemotherapy, and underscore the importance of understanding its mechanism of action in hematopoiesis.
Evidence for the importance of SCF in the maintenance of normal erythropoiesis in vivo comes from studies of mice harboring mutations at the W or SI locus, which encode the c-kit receptor and its ligand, re~pectively.~-'~ Treatment of SI/@ mice with SCF in vivo improves the macrocytic anemia and the mast-cell defect." Conversely, injection of normal adult mice with a neutralizing anti-c-kit monoclonal antibody (MoAb) results in rapid disappearance of hematopoietic progenitor cells from the marrow.15 SCF triggers cell growth by binding to the c-kit receptor, which is a member of the receptor tyrosine kinase family.I6 The c-kit receptor shares a number of structural features with the receptors for platelet-derived growth factor (PDGF) and CSF-1 . I 7 It is likely that binding of SCF, which circulates as a dimer," causes homodimerization of the c-kit receptor and intermolecular tyrosine phosphorylation, thereby initiating signal transduction. 16 The dominant negative nature of certain point mutations in the c-kit receptor tyrosine kinase domain provides support for this concept.I9-*' However, dimerization of the c-kit receptor has not been directly shown in SCF-responsive human hematopoietic cells.
The c-kit receptor is found on normal marrow hematopoietic cells, where it is expressed predominantly on the more primitive A number of human cell lines have been found to respond mitogenically to SCF, but none of these cell lines undergoes growth-factor-induced differentiation.25-27 SCF synergistically enhanced proliferation of M07e cells in the presence of GM-CSF or IL-3:' and induced tyrosine phosphorylation of the c-kit receptor in these cells.26 However, M07e cells do not respond to E~o ,~~ or undergo cytokine-induced erythroid differentiation. Because of the important role of SCF in erythropoiesis both in vivo and in vitro, we characterized c-kit receptors and the effects of SCF on the MB-02 human erythroleukemia cell line, which can undergo downstream erythroid differentiation in response to Epo." We found that MB-02 cells express a single class of high-affinity (& 50 pmol/L) c-kit receptors with approximately 8,000 receptors per cell.
Affinity cross-linking with '"I-SCF showed that the native c-kit receptor in MB-02 cells is of molecular weight 138,000 daltons, and undergoes ligand-induced dimerization. Our results show that SCF enhances MB-02 proliferation in the presence of Epo, and significantly contributes to the expansion of differentiated (hemoglobinized) cells generated. SCF also potentiates the proliferative effects of IL-3 or GM-CSF in MB-02 cells. Thus, the multi-growth factor-responsive MB-02 human erythroleukemia cell line may provide a useful model for additional studies of signal transduction by the c-kit receptor.
MATERIALS AND METHODS
Growth factors. Purified recombinant human SCF expressed in Escherichia coli was provided by Amgen (Thousand Oaks, CA) and was used for cell culture at a concentration of 0.5 to 100 ng/mL. Purified recombinant human GM-CSF (10' U/mg) expressed in BHK cells was a gift of Dr Kenneth Kaushansky (University of Washington, Seattle) and was used at a concentration of 1 to 5 ng/mL. Partially purified baby hamster kidney (BHK)-expressed human recombinant Epo (6,000/mg)2g was used for cell culture at final concentrations of 2.5 to 5 U/mL. Purified recombinant human IL-3 (Genetics Institute, Cambridge, MA) was used at a concentration of 5 U/mL. For one experiment, purified recombinant human IL-3 from a different source (Genzyme, Cambridge, MA) was used at a concentration of 0. I to 1 .O ng/mL.
Cell culture. The establishment and characterization of the MB-02 cell line was described previously?8 MB-02 cells were maintained in RPMI 1640 (MA Bioproducts, Walkersville, MD) supplemented with 5% heat-inactivated fetal calf serum (FCS; Hyclone, Logan, UT), 5% normal human serum, I mmol/L pyruvate, and GM-CSF in 5% CO2 at 37°C. When large numbers of cells were required, the cells were grown in T-25 flasks. For analysis of growth curves, the cells were washed twice in RPMI 1640, then seeded at a concentration of 0.5 to 1 X 105/mL in RPMI 1640 with 5% FCS and 5% human serum in 24-well plates (Costar, Pleasanton, CA). The cells were cultured with no added growth factor, GM-CSF, IL-3, Epo, SCF, or combinations of growth factors. Trypan blue-excluding cells were quantitated using a hemocytometer. To induce erythroid differentiation, the MB-02 cells were cultured in Epo (5 U/ mL) for approximately 3 weeks, as required to reach advanced stages of maturation. For some experiments, MB-02 populations enriched for more mature erythroid cells were obtained by direct immune adherence with MoAb SFL 23.6, which recognizes an antigen present on late erythroid progenitors (colony-forming unit erythroid [CFU-E]) and erythroid precursor cells."
Globin analysis. The presence of globin in uninduced or induced MB-02 cells was assessed by immunofluorescence, using previously described antiglobin chain-specific MoAbs (anti+, anti-y, anti-t, anti-{), and by isoelectric focusing of globin chains, according to previously described meth~dology.~' Cytocentrifuge-prepared smears fixed with methanol were used for labeling with the MoAbs. Lysates of MB-02 cells labeled with 'H-leucine (125 Ci/ mmol; Amersham, Arlington Heights, IL) in leucine-free medium were used for isoelectric focusing. After focusing, the gels were fixed, treated with Enhance (Dupont, Boston, MA), dried, and subjected to fluorography and densitometry. An acid benzidine test was used for the detection of heme."
Quantitation of SCF and Epo receptors. SCF was iodinated using the chloramine-T method, as previously described." The radiologic-specific activity was determined by self displacement analys~s,'~ and was generally 2,000 to 2,500 Ci/mmol. Iodination of SCF did not alter its receptor binding characteristics," or colony-stimulating activity." Log-phase growth MB-02 cells were added to a premixed, precooled solution of '"I-SCF (10 pmol/L to 4.4 nmol/ L) with or without a 100-fold excess of unlabeled SCF in binding buffer (RPMI 1640 supplemented with 50 mmol/L HEPES [pH 7.41, 1% bovine serum albumin [BSA], 0.1% azide, and 10 pg/mL cytochalasin B).33 The final incubation volume was 100 pL. After a 4-hour incubation at 15°C in a shaking incubator, the cells were sedimented through a phthalate oil mixture to separate cell-associated I2%SCF from free 1251-SCF." The cell pellets were clipped off, and 1251 was quantitated in both pellets and supernatants in a Packard 5330 gamma counter (Packard Instrument CO, Downers Grove, IL).
Purified recombinant human Epo was obtained from Amgen, 'Z51-Epo (300 to 900 Ci/mmol) was obtained from Amersham, and Epo receptors were quantitated as previously with minor modifications. MB-02 cells were added to a mixture of 1251-Epo (30 pmol/L to 2.2 nmol/L) with or without a 100-fold excess of unlabeled Epo in binding buffer containing 0.1% azide and IO pg/ mL cytochalasin /3 as described above. After 2 hours of incubation at 37°C in a shaking incubator, the MB-02 cells were sedimented through phthalate oil and cell-associated and free i251-Epo were quantitated. All determinations were performed in duplicate. Binding data were analyzed using the ligand program. IN) . Insoluble cellular debris was removed by centrifuging the cell lysate for 3 minutes at 4°C in a Beckman Microfuge l l (Beckman, Palo Alto, CA). Proteins cross-linked to SCF were immunoprecipitated with rabbit polyclonal anti-SCF antibody 1334 (raised against purified E coli-derived human SCF, Amgen) and Staph A (Calbiochem, San Diego, CA). The precipitated proteins were suspended in 2X sample buffer (0.125 mmol/L Tris HCl [pH 6.81, 4% sodium dodecyl sulfate (SDS), 0.008% bromphenol blue, 20% glycerol, [*50 mmol/L dithiothreitol]), boiled for 3 minutes, and analyzed on a 5% polyacrylamide 14C-labeled molecular weight markers (range, 14,300 to 200,000 daltons; Amersham) and unlabeled molecular weight markers (range, 14,000 to 340,000; Boehringer Mannheim) were used. Unlabeled molecular weight markers were identified by silver staining of the gel (Bio-Rad, Richmond, CA). Radiolabeled proteins were detected by autoradiography.
RNAse protection assay for c-kit and SCF messenger RNA @RNA). RNA probes for c-kit and SCF mRNA were made by runoff transcription of cDNA regions cloned in @EM vectors Afinity cross-linking.
For personal use only. Samples of cell lysate or RNA standard were hybridized to the probe as previously de~cribed.'~ All hybridizations were performed in duplicate. The quantity of gene-specific RNA in each sample was calculated from a curve generated using the sensestrand RNA standards.
RESULTS
Efects of SCF on survival and proliferation of MB-02 cells. In the absence of growth factors, the MB-02 cells died before day 6, indicating the absolute requirement for exogenous growth factors. SCF alone modestly prolongs the survival of MB-02 cells (Fig I) , but does not stimulate their proliferation. However, in the presence of Epo, SCF-stimulated proliferation of MB-02 cells in a dose-dependent manner (Fig I) . At a concentration of 0.5 ng/mL, SCF had no detectable effect on MB-02 proliferation (data not shown), but SCF concentrations of 5 ng/mL and 25 ng/mL provided potent stimulation of MB-02 growth in the presence of Epo in a synergistic manner (Fig 1) . GM-CSF stimulated vigorous growth of MB-02 cells without substantial erythroid differentiation. The minimal concentration of GM-CSF for stimulation of MB-02 proliferation was between 0.05 and 0.1 ng/mL (Fig 2) . At optimal doses of GM-CSF, little additive effect of SCF on MB-02 growth was observed (Table 1) . However, at lower concentrations of GM-CSF (0.15 to 0.5 ng/mL), the addition of low concentrations of SCF enhanced cell growth (Tables I and 2 ). Like SCF, IL-3 enhanced the survival of MB-02 cells ( Table 2 ). The addition In experiment 1, cultures were inoculated with 0.9 x lo5 ME-02 cells on day 0. Growth factors were used at the following concentrations: Epo 2.5 U/mL. SCF 50 ng/mL, IL-3 5 U/mL, and GM-CSF 0.15 ng/mL. SR-1 ascites (final dilution, 1:l.OOO) was added on day 0, and cell counts were performed on day 5. In experiment 2, cultures were inoculated with 1 .O X 1 O5 MB-02 cells on day 0. Growth factors were used at the following concentrations: Epo 2.0 U/mL, SCF 50 ng/mL, 11-3 0.1 ng/mL or 1 .O ng/mL. The lower concentration of 11-3 used (0.1 ng/mL; Genzyme) is equivalent to 2 to 5 U/mL of IL-3. SR-1 ascites (1 : 1.000) was added on day 0, and cell counts were performed on day 7. Three additional experiments gave similar results.
Experiment 2
Abbreviation: ND, not done.
cells. The addition of SR-1 to cultured MB-02 cells resulted in inhibition of SCF-stimulated growth (Table 2) . Of note, MB-02 growth in the presence of Epo plus IL-3 (without added SCF) was also partially inhibited by SR-1. Efleects of SCF on erythroid diferentiation of MB-02 cells. Undifferentiated MB-02 cells show very few benzidine-positive cells (Fig 3) and few cells positive for y-globin (Figs 3 and 4) . Only rare cells with slight positivity for 0-globin are found. When Epo is added, the number of cells positive for 8-or y-globin increases (Fig 4) . After 2 to 3 weeks of culture with Epo, the relative synthesis of y-to 8-globin is decreased because of accumulation of more mature cells (Fig 5) . The fact that p-globin synthesis is associated with the presence of more mature cells was shown by separating 18 day Epo-induced cells into more or less mature cells on the basis of cytoadherence to MoAb SFL Table 3 . The SR-1 MoAb Blocks Binding of '*"l-SCF to ME-02 Cells 02 cells growing in GM-CSF. In two separate experiments, the MB-02 cells were found to contain 1 1 copy of SCF mRNA per cell, which is at the lower unit of detection for this assay, suggesting that these cells do not produce SCF.
Receptor stiidie.y. Quantitative binding experiments with '"I-SCF showed that MB-02 cells display a single class of high-affinity c-kit receptors (Fig 6) . The binding affinity for SCF was 55 f 6 pmol/L (mean 2 SEM of four experiments), similar to that ofthe c-kit receptor found on normal human marrow mononuclear cells.4' The number of c-kit receptors per MB-02 cell was approximately 8,000 (Fig 6) . Epo-induced erythroid differentiation of MB-02 cells was associated with a decrease in binding of '251-SCF ( Table 4) .
Affinity cross-linking of '"I-SCF to its receptor on MB-02 cells showed two major bands of approximate molecular weight 155,000 and 310,000 daltons (Fig 7) , which likely represent the monomeric and dimeric forms of the c-kit receptor. These radiolabeled complexes were not seen when affinity cross-linking was performed in the presence of excess unlabeled SCF (Fig 7, lane 6) . Analysis in the presence and in the absence of the reducing agent dithiothreitol gave similar results (data not shown). Affinity cross-linking in the presence of increasing quantities of "'I-SCF showed no significant change in the relative amounts of the low and high molecular species (Fig 7) . After subtracting the contribution ofthe E coli-expressed SCF in the cross-linked complex, the estimated molecular weight ofthe monomeric c-kif receptor on MB-02 cells was found to be approximately 137,000 daltons. In four additional experiments, the estimated molecular weight of the monomeric MB-02 c-kit receptor was found to be 138,000 f 2,000 daltons (mean * SEM).
Epo receptors were quantitated by saturation binding experiments with 12SI-Epo. MB-02 cells exhibit a single class of MB-02 cells were cultured in the presence of Epo for 17 days. An enriched population of more mature erythroid cells was obtained by direct immune adherence with MoAb SFL 23.6. In this experiment, 73% of the Epo-induced MB-02 cells were SFL 23.6 adherent (more mature), and 27% of the cells were SFL 23.6 nonadherent (less mature). Adherent or nonadherent MB-02 cells (lo') were incubated with 420 pmol/L "' I-SCF 2 42 nmol/L unlabeled SCF for 4 hours at 15°C. The cpmbound data are presented as the average of duplicate determinations. The fraction of cells containing @-globin was determined by immune fluorescence of fixed preparations. Labeling with anti-?-globin showed positively in greater than 90% of the MB-02 cells in both populations.
Epo receptors (Fig 8) . The binding affinity for Epo was 270 f 47 pmol/L (mean f SEM of three experiments). This is similar to the binding affinity of the Epo receptor on cultured human peripheral blood BFU-E p r~g e n y '~ and on other human erythroleukemia cell MB-02 cells proliferating in GM-CSF display approximately 250 Epo receptors per cell, which is similar to levels found in normal cells.37 BM culture-initiating cells, cells that are also influenced by other early acting cytokines such as IL-I, IL-3, or IL-6.7*8. 45 We report here that SCF in synergy with Epo enhances both the proliferation and the erythroid differentiation of MB-02 cells. The ability of SCF to potentiate the differentiating effect of Epo points to an effect of SCF on more mature cells. of the CFU-E-type, that are dependent only on Epo. A similar effect of SCF, to enhance the survival and amplification of normal CFU-E, has recently been r e~o g n i z e d .~~ Thus, the ability of SCF to potentiate Epo-induced differentiation of MB-02 cells is observed in normal cells as well, and reflects a normal property of SCF.
MB-02 cells undergo a shift to @-globin expression under the influence of Epo.*' Although @-globin RNA increased, there was no decrease in y-globin RNA after Epo-induced differentiation of MB-02 cells: the reasons for these paradoxical findings were not clear.*' In our present experiments, by separating the most mature from the immature MB-02 cells, we provide a new way for looking into these findings. Our data suggest that indeed the more mature MB-02 cells contain more @-globin and relatively less y-globin, while the immature cells express predominantly y-globin. Thus, the paradox is caused by the fact that a mixed population of differentiated and nondifferentiated cells exist during Epo-induced erythroid differentiation of MB-02 cells. Our data, as well as a similar effect of Epo on a murine cell do not discriminate whether Epo directly induces synthesis of @-globin or promotes the maturation of MB-02 cells and hence the presence of a cellular environment favoring @-rather than y-globin synthesis. Other human erythroleukemia cell lines have shown expression of @-globin after exposure to chemical inducers (KMOE, Ku812, and OCIM2); however, none display the shift in P-globin expression with maturation as observed in MB-02 cells under the influence of Epo.
For
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Later stages of erythroid differentiation (late BFU-E and CFU-E) are Epo-dependent for their proliferation and differentiation. However, as differentiation proceeds to completion, proliferation is curtailed. The fact that Epo-responsive MB-02 cells continue to proliferate in response to Epo plus SCF reflects their incomplete maturation, and the fact that earlier cells with a good proliferative capacity are still present despite the continuous presence of Epo.
The SR-1 antibody blocked I2%SCF binding to the c-kit receptor, and also blocked the effects of SCF on MB-02 proliferation. The antibody did not affect MB-02 proliferation in the presence of GM-CSF, but diminished MB-02 growth in the presence of IL-3 plus Epo. Two distinct major experimental approaches suggest that participation of the c-kit receptor is necessary for normal cellular response to IL-3 in vitro: the use of antisense oligonucleotides specific for the c-kit receptor and the use of neutralizing anti-c-kit receptor MoAbs. Ablating production of the c-kit receptor using antisense oligonucleotides (but not sense or missense oligonucleotides) inhibited the formation of myeloid colonies from human marrow hematopoietic cells in the presence of IL-3, but not GM-CSF,"' and inhibited erythroid colony growth in the presence of IL-3 plus Epo, or SCF plus E~o .~~ Myeloid colony growth in the presence of GM-CSF plus IL-3 was not affected by c-kit receptor antisense oligonucleotides in the latter report.49 The SR-I anti-c-kit MoAb has been found to block BFU-E colony growth from normal adult human hematopoietic cells cultured in the presence of Epo with or without IL-3; myeloid colony growth in the presence of GM-CSF was less dramatically a f f e~t e d .~~?~~ Certain of these data could be explained by SCF present in serum,5o or by the possibility that CD34+ cells may make small quantities of SCF, which dramatically potentiates the effects of Epo and IL-3. However, as described in the present report, MB-02 cells lack SCF mRNA, yet their ability to proliferate in IL-3 plus Epo is inhibited by the SR-1 antibody. Taken together, these data suggest that the ability of human hematopoietic cells to respond normally to IL-3 in vitro requires the cell surface expression and function of the c-kit receptor.
Because MB-02 cells express functional receptors for both SCF and Epo, we sought to characterize these receptors on MB-02 cells. The MB-02 c-kit receptor is similar to that of normal human hematopoietic cells in several respects. Thus, the MB-02 multi-growth factor-responsive erythroleukemia cell line provides a model in which to examine regulation of c-kit mRNA and protein production during proliferation and differentiation.
The molecular weight of the monomeric c-kit receptor protein in MB-02 cells determined by affinity cross-linking with 1251-SCF is similar to that found in normal human marrow cells.35 However, a major higher molecular weight I2%SCF cross-linked complex was also found in MB-02 cells. Two observations suggest that this species may represent a dimer of the c-kit receptor: its estimated molecular weight is approximately twice that of the monomeric 12% SCF-c-kit receptor complex, and it is completely abolished by cross-linking in the presence of unlabeled SCF. Affinity cross-linking with human marrow cells, human tumor cell lines, and murine cells has also suggested the presence of a high molecular weight complex at the top of the but the electrophoresis conditions used in these reports were not designed to resolve the molecular weight of this complex. Metabolic labeling in a variety of cell lines and in normal mast cells has identified two major monomeric forms of the c-kit receptor protein (molecular weight -140,000 to 160,000 daltons and -120,000 to 130,000 d a l t~n s ) ; " ,~~*~~ differences in carbohydrate content may explain the differences in the molecular weights of the receptor observed on the various cell lines. In contrast, affinity cross-linking of '251-SCF to the c-kit receptor in MB-02 cells and other showed the -140,000 dalton but not the -125,000 dalton monomeric form of the receptor. These data suggest that the 125,000 dalton receptor protein does not bind '251-SCF at the cell surface. The 125,000 dalton c-kit receptor protein may be converted into the higher molecular weight species intracellularly by posttranslational m~dification.~~ Alternatively, the 125,000 dalton receptor protein may be present on the cell surface, but incapable of binding SCF. Whether both forms of the c-kit receptor protein play a role in signal transduction in vivo remains to be determined.
